Tirzepatide Vs Semaglutide Vs Retatrutide
Tirzepatide vs Semaglutide vs Retatrutide: Trials Compared
Published by Peptara Labs · Updated · How we research and check our pages
The short answer
Tirzepatide vs semaglutide vs retatrutide differ in how many receptors each one targets. Semaglutide hits one receptor, tirzepatide hits two and retatrutide hits three. In SURMOUNT-1, the weight change in the highest tirzepatide dose group was about 22.5 percent at 72 weeks, counting as if all stayed on treatment. Counting all who joined, the highest dose group had about 20.9 percent. In STEP 1, the semaglutide group had about 14.9 percent at 68 weeks, counting all who joined. In a phase 2 trial, the highest retatrutide dose group had about 24.2 percent at 48 weeks, counting as if all stayed on treatment. These figures come from separate trials, so they cannot be compared directly.
This page is general educational information, research-use framing only, not medical advice. Research-grade material is for laboratory research only, not for human use.
Sources for this section: STEP 1, Wilding et al., N Engl J Med 2021; SURMOUNT-1, Jastreboff et al., N Engl J Med 2022; retatrutide phase 2, Jastreboff et al., N Engl J Med 2023.
What is the difference between tirzepatide, semaglutide, and retatrutide?
The difference is how many hormone receptors each one targets: semaglutide hits one, tirzepatide hits two, and retatrutide hits three.
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide adds the GIP receptor, making it a dual agonist. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist. In SURMOUNT-1, the highest tirzepatide dose group had a mean weight change of about 22.5 percent at 72 weeks, counting as if all stayed on treatment. Counting all who joined, it was about 20.9 percent in that highest dose group. In STEP 1, the semaglutide group had about 14.9 percent at 68 weeks, counting all who joined. In a phase 2 trial, the highest retatrutide dose group had about 24.2 percent at 48 weeks, counting as if all stayed on treatment.
Sources for this section: STEP 1, Wilding et al., N Engl J Med 2021; SURMOUNT-1, Jastreboff et al., N Engl J Med 2022; retatrutide phase 2, Jastreboff et al., N Engl J Med 2023.
How do the three compounds compare on the key numbers?
Here is the three-column view of mechanism, reported weight change, approval status, and half-life.
The weight figures on this page were counted in one of two ways. One way counts everyone who joined the trial, whether or not they stayed on treatment. The other counts people as if all stayed on treatment. In the table, the words in parentheses are each paper's own name for how it counted.
| Feature | Tirzepatide | Semaglutide | Retatrutide |
|---|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 agonist | GIP + GLP-1 + glucagon triple agonist |
| Reported weight change and how it was counted | about 22.5 percent at 72 weeks, highest dose group, counting as if all stayed on treatment (the efficacy estimand); about 20.9 percent, counting all who joined (the treatment-regimen estimand) | 15.3 kg, about 14.9 percent at 68 weeks, semaglutide group, counting all who joined (the treatment policy estimand) | about 24.2 percent at 48 weeks, highest dose group, counting as if all stayed on treatment (the efficacy estimand) |
| Trial | SURMOUNT-1, NEJM | STEP 1, NEJM | Phase 2, NEJM |
| Half-life | about 5 days | about 7 days | about 6 days |
| Approval status | Approved for named indications by major regulators | Approved for named indications by major regulators | Investigational, no completed phase 3 approval at time of the cited trial |
The half-life figures are approximate.
Sources for this section: STEP 1, Wilding et al., N Engl J Med 2021; SURMOUNT-1, Jastreboff et al., N Engl J Med 2022; retatrutide phase 2, Jastreboff et al., N Engl J Med 2023; Overgaard et al., Diabetes Ther 2019; Coskun et al., Mol Metab 2018; Coskun et al., Cell Metab 2022.
How much weight change did each trial report?
In a phase 2 study, the weight change at 48 weeks was about 24.2 percent in the highest retatrutide dose group, counting as if all stayed on treatment. A later phase 3 trial, TRIUMPH-4, was published in 2026. It enrolled adults with painful knee osteoarthritis and overweight or obesity. At 68 weeks, counting all who joined (a treatment-policy strategy), its lower dose group had a weight change of about 20.0 percent. Its higher dose group had about 23.7 percent and its placebo group about 4.6 percent, also counting all who joined.
In STEP 1, the semaglutide group had a mean loss of 15.3 kg at 68 weeks, counting all who joined. In SURMOUNT-1, the highest tirzepatide dose group's weight change was about 22.5 percent at 72 weeks, counting as if all stayed on treatment. Counting all who joined, the same highest dose group had about 20.9 percent. SURPASS-2 compared tirzepatide with semaglutide directly in people with type 2 diabetes. It reported greater weight reduction with tirzepatide. SURMOUNT-5 compared them directly in adults with obesity but without type 2 diabetes. At 72 weeks, it reported greater weight reduction in its tirzepatide group than in its semaglutide group. No completed trial has placed all three side by side.
Sources for this section: retatrutide phase 2, Jastreboff et al., N Engl J Med 2023; TRIUMPH-4, Schnitzer et al., N Engl J Med 2026; STEP 1, Wilding et al., N Engl J Med 2021; SURMOUNT-1, Jastreboff et al., N Engl J Med 2022; SURPASS-2, Frías et al., N Engl J Med 2021; SURMOUNT-5, Aronne et al., N Engl J Med 2025.
How did the three trials differ?
The three headline figures come from trials that differ in length, size, phase and who took part. All three took adults who had obesity, or who were overweight and had a health problem linked to weight.
- Semaglutide, STEP 1: 68 weeks, 1,961 adults, none with diabetes.
- Tirzepatide, SURMOUNT-1: a phase 3 trial, 72 weeks, 2,539 adults, none with diabetes.
- Retatrutide: a phase 2 trial, 48 weeks, 338 adults.
- SURPASS-2, a direct comparison: a phase 3 trial of tirzepatide against semaglutide, 40 weeks, 1,879 people with type 2 diabetes.
- SURMOUNT-5, a direct comparison: a phase 3b trial of tirzepatide against semaglutide, 72 weeks, 751 adults with obesity, none with type 2 diabetes.
SURPASS-2 included only people with type 2 diabetes, so it answers a different question.
Sources for this section: STEP 1, Wilding et al., N Engl J Med 2021; SURMOUNT-1, Jastreboff et al., N Engl J Med 2022; retatrutide phase 2, Jastreboff et al., N Engl J Med 2023; SURPASS-2, Frías et al., N Engl J Med 2021; SURMOUNT-5, Aronne et al., N Engl J Med 2025.
What about side effects across the three?
The most commonly reported issues in these trials were gastrointestinal, such as nausea, and they were most frequent early in the trials.
Nausea, diarrhea and constipation were among the most common reported events in STEP 1, SURMOUNT-1 and the phase 2 trial. Retatrutide adds a glucagon target. Its phase 2 study looked at side effects and safety as well as weight change. The STEP 1 extension followed people for a year after semaglutide was stopped. They regained weight. SURMOUNT-4 switched some people from tirzepatide to placebo. Those people regained weight. In STEP 5, the semaglutide group's weight loss leveled off after about week 60 and held to week 104.
Sources for this section: STEP 1, Wilding et al., N Engl J Med 2021; SURMOUNT-1, Jastreboff et al., N Engl J Med 2022; retatrutide phase 2, Jastreboff et al., N Engl J Med 2023; STEP 1 extension, Wilding et al., Diabetes Obes Metab 2022; SURMOUNT-4, Aronne et al., JAMA 2024; STEP 5, Garvey et al., Nat Med 2022.
Which comparison page should I read next?
Read the pairwise page that matches the two compounds being compared, since each covers its own trial detail.
For a single-target versus dual-target look, see the semaglutide versus tirzepatide page. For the triple versus dual question, see the retatrutide versus tirzepatide page. This hub is the three-way overview; the pairwise pages go deeper on each matchup.
Tirzepatide Vs Semaglutide Vs Retatrutide: FAQ
Is retatrutide approved the same way as the other two?
No. At the time of the cited phase 2 trial, retatrutide was investigational with no completed phase 3 approval, while semaglutide and tirzepatide were already approved for named indications by major regulators.
Does more receptor targeting always mean more weight loss?
These three trials cannot show whether the number of receptor targets affects weight loss. SURMOUNT-1 reported a weight change of about 22.5 percent in its highest tirzepatide dose group at 72 weeks, counting as if all stayed on treatment. Counting all who joined, that highest dose group had about 20.9 percent. STEP 1 reported about 14.9 percent in its semaglutide group at 68 weeks, counting all who joined. A phase 2 trial reported about 24.2 percent in its highest retatrutide dose group at 48 weeks, counting as if all stayed on treatment.
Has any study compared these compounds directly?
Yes, tirzepatide and semaglutide have been compared head to head, but no trial has compared all three at once. SURPASS-2, in people with type 2 diabetes, reported greater weight reduction with tirzepatide. SURMOUNT-5, in adults with obesity but no type 2 diabetes, also found greater weight loss with tirzepatide at 72 weeks.
What happened to weight after withdrawal in trials?
In the STEP 1 extension, people regained weight in the year after semaglutide was stopped. In SURMOUNT-4, people who switched from tirzepatide to placebo regained weight.
What are the half-lives of the three?
Each has a multi-day half-life, roughly 5 to 7 days.
Sources for this section: retatrutide phase 2, Jastreboff et al., N Engl J Med 2023; STEP 1, Wilding et al., N Engl J Med 2021; SURMOUNT-1, Jastreboff et al., N Engl J Med 2022; SURPASS-2, Frías et al., N Engl J Med 2021; SURMOUNT-5, Aronne et al., N Engl J Med 2025; STEP 1 extension, Wilding et al., Diabetes Obes Metab 2022; SURMOUNT-4, Aronne et al., JAMA 2024; Overgaard et al., Diabetes Ther 2019; Coskun et al., Mol Metab 2018; Coskun et al., Cell Metab 2022.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PMID 37366315.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID 34170647.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID 35441470.
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945. PMID 38078870.
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4. PMID 36216945.
- Overgaard RV, Delff PH, Petri KCC, et al. Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. Diabetes Therapy. 2019;10(2):649-662. doi:10.1007/s13300-019-0581-y. PMID 30788808.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009. PMID 30473097.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340.
- Schnitzer TJ, Hunter DJ, Conaghan PG, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity (TRIUMPH-4). New England Journal of Medicine. Published online November 8, 2026. doi:10.1056/NEJMoa2610676. PMID 43001755.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394. PMID 40353578.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Research material is for laboratory research only, not for human use.